| URL | https://www.thomasnet.com/insights/thermo-fisher-s |
| Source | Thomas Insights |
| Date Published | 03/24/2021 |
| Author Name | Mike Hockett |
| Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
| Company/Division name | Thermo Fisher Scientific |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2021 |
| Year reshoring implemented or to be implemented: | 2022 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 600 |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | bioprocessing, biopharma, single-use technologies |
| What domestic positive factors made reshoring more attractive? | Lead time/Time to market, Other, Covid-19 |